SCHEDULE 13G/A: Walters Group Files Amended 13G, Disclosing Continued 9.1% Stake in Zentalis Pharmaceuticals
Beneficial Ownership Disclosure Amendment
William T. Walters, Susan B. Walters, and The Walters Group have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 6,500,000 shares, representing 9.1% of Zentalis Pharmaceuticals, Inc.'s common stock.
Summary
- The filing is an Amendment No. 2 to a Schedule 13G, filed by William T. Walters, The Walters Group (TWG), and Susan B. Walters (collectively, the "Reporting Persons").
- The Reporting Persons collectively beneficially own 6,500,000 shares of Zentalis Pharmaceuticals, Inc.'s Common Stock, $0.001 par value per share.
- This ownership represents 9.1% of the issuer's class of securities.
- All 6,500,000 shares are held with shared voting power and shared dispositive power among the Reporting Persons.
- The Walters Group is organized as a Nevada general partnership, while William T. Walters and Susan B. Walters are U.S. citizens.
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would significantly alter sentiment. The continued significant stake by the Walters Group could be seen as a neutral to slightly positive signal of investor confidence.
Positives
- The continued significant stake of 9.1% in Zentalis Pharmaceuticals, Inc. by the Walters Group indicates ongoing investor confidence and a stable large shareholder base.
Future Outlook
The document does not provide any forward-looking statements or guidance from Zentalis Pharmaceuticals, Inc. or the Reporting Persons regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine disclosure of beneficial ownership by a significant shareholder group and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure and Intent | The Reporting Persons certify that their securities are not held for the purpose of changing or influencing control of the issuer, but explicitly reserve the right to engage in activities solely in connection with a nomination under Rule 240.14a-11. | 01/21/2025 | This clarifies the passive nature of the investment while retaining the option for potential future engagement in corporate governance through director nominations, which could be a precursor to more active shareholder involvement. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake, potentially signaling stability and confidence from a major investor group.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of event which requires filing of this statement / Certification date of the Schedule 13G Amendment No. 2. |
Keywords
Zentalis Pharmaceuticals, ZNTL, Schedule 13G, beneficial ownership, common stock, Walters Group, William T. Walters, Susan B. Walters, institutional ownership, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.